Ask Questions, Get Industry Insights … Instantly

Save time and get answers to complex questions with AI chat

Recent Questions

Dabrafenib btd date 2023?
The expiration date of the key patent for guselkumab?
Abbvie humira patent cliff navigation success?
How to apply for vascepa's patient assistance?
Generic brand for latisse?

Oseltamivir?

See the DrugPatentWatch profile for Oseltamivir

Oseltamivir is an antiviral medication used to treat and prevent influenza (the flu) in adults and children. It works by inhibiting the neuraminidase enzyme, which is crucial for the release of new virus particles from infected cells, thereby limiting the spread of the virus within the body [1].

What is Oseltamivir Used For?

Oseltamivir is prescribed for two primary purposes: treatment of acute, uncomplicated influenza and prophylaxis (prevention) of influenza. For treatment, it can reduce the duration of flu symptoms and potentially decrease the risk of complications. For prevention, it is used when an individual has been exposed to the flu virus, such as in a household setting, or during periods of high community influenza activity [1].

How Long Does Oseltamivir Treatment Last?

A typical course of oseltamivir for treating influenza lasts for five days, with doses taken twice daily [1]. For prophylaxis, the duration of treatment can vary depending on the situation, but it is generally continued for as long as the risk of exposure exists or as recommended by a healthcare provider [1].

When Does Oseltamivir Patent Expiration Occur?

The primary patent for oseltamivir phosphate, the active ingredient in Tamiflu, has expired. DrugPatentWatch.com tracks patent expirations and exclusivity periods for pharmaceuticals. While the core patents have expired, there may be other related patents covering specific formulations, manufacturing processes, or new uses that could still be in effect [2].

Can Generic Versions of Oseltamivir Be Manufactured?

Following the expiration of key patents, generic versions of oseltamivir can be manufactured and marketed. This allows for the availability of lower-cost alternatives to the brand-name drug, increasing accessibility for patients [2].

Who Makes Oseltamivir?

The original brand-name drug, Tamiflu, was developed and is marketed by Roche. However, with patent expirations, numerous pharmaceutical companies now produce and distribute generic versions of oseltamivir worldwide [2].

What Are the Side Effects of Oseltamivir?

Common side effects associated with oseltamivir include nausea, vomiting, headache, and abdominal pain. Less common but more serious side effects have been reported, including neuropsychiatric events, particularly in children and adolescents, though a causal relationship is not definitively established in all cases. Patients should report any unusual symptoms to their healthcare provider [1].

How Does Oseltamivir Work to Fight the Flu?

Oseltamivir is a neuraminidase inhibitor. The influenza virus uses the neuraminidase enzyme to cleave sialic acid residues on the surface of host cells, which is necessary for the release of newly formed virions. By inhibiting this enzyme, oseltamivir prevents the efficient spread of the virus from infected cells to uninfected ones [1].

What Are the Alternatives to Oseltamivir for Flu?

Other antiviral medications are available for the treatment and prevention of influenza, including zanamivir (Relenza), peramivir (Rapivab), and baloxavir marboxil (Xofluza). Each of these drugs has a different mechanism of action and a unique profile of efficacy, side effects, and resistance patterns [3].

What Are the Risks of Not Treating the Flu?

Influenza can lead to serious complications, including pneumonia, bronchitis, sinus infections, and ear infections. In some cases, it can worsen chronic health problems, such as asthma or heart failure, and can be fatal, particularly for vulnerable populations like the elderly, young children, and individuals with weakened immune systems [1].

How is Oseltamivir Regulated?

Oseltamivir, like all medications, is regulated by health authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). These agencies review extensive clinical trial data to ensure the drug's safety, efficacy, and quality before approving it for marketing. Post-market surveillance continues to monitor for any adverse events [1].

Sources:
[1] https://www.drugs.com/oseltamivir.html
[2] https://www.drugpatentwatch.com/
[3] https://www.cdc.gov/flu/treatment/whatyoucan-drug-info.htm

Other Questions About Oseltamivir :

Oseltamivir phosphate api suppliers in india? Oseltamivir phosphate api specification? Oseltamivir capsules ip 75 mg? Patente de oseltamivir? How much is oseltamivir? Oseltamivir harga? Generic oseltamivir manufacturers?

AI-Drug Label Prescribing Information Alignment Report

62

62%

Grade C

Partial

Partially Aligned

Patient Risk: Moderate

Summary

Some labeling-aligned statements are present (indications, core mechanism at a high level, common adverse reactions, and existence of neuropsychiatric reports). However, multiple specifics conflict with the label (adult/teen prophylaxis dosing frequency and duration language), and several safety/usage limitations from the label are omitted (e.g., vaccine substitute limitation, renal impairment restriction).

Category Scores

Indication

78

Good

Dosage

45

Partial

Contraindications

20

Poor

Warnings

60

Partial

DrugInteractions

0

Poor

SpecificPopulations

35

Partial

AdverseReactions

70

Good

Administration

55

Partial

Accurate Statements

Oseltamivir is an antiviral medication used to treat influenza (the flu) in adults and children.

1.1 Treatment of Influenza; indicated for treatment of acute, uncomplicated influenza A and B in patients 2 weeks of age and older.

Oseltamivir is an antiviral medication used to prevent influenza (the flu) in adults and children.

1.2 Prophylaxis of Influenza; indicated for prophylaxis of influenza A and B in patients 1 year and older.

Oseltamivir works by inhibiting the neuraminidase enzyme.

12.1 Mechanism of Action; and label includes neuraminidase inhibitor context in Microbiology.

The neuraminidase enzyme is crucial for the release of new virus particles from infected cells.

12.4 Microbiology (neuraminidase-related mechanism/resistance discussion).

By inhibiting neuraminidase, oseltamivir limits the spread of the virus within the body.

12.4 Microbiology; and general mechanism consistent with preventing efficient spread (label-level mechanism discussion).

Oseltamivir is prescribed for treatment of acute, uncomplicated influenza.

1.1 Treatment of Influenza: indicated for treatment of acute, uncomplicated illness due to influenza A and B.

For treatment, oseltamivir can reduce the duration of flu symptoms.

14.1 Treatment of Influenza: reduced time to improvement with 75 mg twice daily for 5 days.

Common side effects of oseltamivir include nausea, vomiting, headache, and abdominal pain.

6.1 Clinical Trials Experience: most common adverse reactions include nausea, vomiting, headache; gastrointestinal adverse events described in pediatric studies (and GI events are part of the adverse reaction profile).

Less common but more serious side effects of oseltamivir have been reported, including neuropsychiatric events.

5.2 Neuropsychiatric Events (postmarketing reports of delirium/abnormal behavior leading to injury).

Neuropsychiatric events have been reported particularly in children and adolescents.

5.2 Neuropsychiatric Events: label notes cases in patients with influenza who were receiving oseltamivir; pediatric emphasis is reflected in the label’s discussion context.

A causal relationship between oseltamivir and neuropsychiatric events is not definitively established in all cases.

5.2 Neuropsychiatric Events (label discusses postmarketing reports and the need to evaluate risks/benefits; it does not establish definitive causality in all cases).

Oseltamivir is a neuraminidase inhibitor.

12.1 Mechanism of Action (antiviral drug with activity against influenza virus; neuraminidase inhibition context used in Microbiology and clinical pharmacology).

Other antiviral medications available for treatment and prevention of influenza include zanamivir (Relenza), peramivir (Rapivab), and baloxavir marboxil (Xofluza).

Microbiology/clinical pharmacology section discusses resistance cross-resistance patterns with zanamivir (and mentions neuraminidase/M2 classes). The label excerpts provided do not list peramivir or baloxavir by name; therefore this statement is only partially supported by provided excerpts.

Post-market surveillance continues to monitor for adverse events related to oseltamivir.

Implicitly consistent with presence of postmarketing experience/adverse reactions (6.2 Postmarketing Experience).

Unsupported Statements

For treatment, oseltamivir can potentially decrease the risk of complications.

The provided label excerpts do not state that oseltamivir decreases the risk of complications; only time to improvement is described.

For prevention, oseltamivir is used when an individual has been exposed to the flu virus, such as in a household setting.

Label supports post-exposure prophylaxis initiation within 48 hours after close contact, but the specific example 'household setting' is not stated in the provided excerpts.

For prevention, oseltamivir is used during periods of high community influenza activity.

Label supports seasonal prophylaxis during a community outbreak, but 'high community influenza activity' phrasing is not directly supported by the provided excerpts.

For prophylaxis, oseltamivir is generally continued as long as the risk of exposure exists.

Label specifies durations (at least 10 days after close contact up to 6 weeks during community outbreak; up to 12 weeks in immunocompromised patients). 'As long as risk exists' is not the label phrasing and may be broader than what the label states.

For prophylaxis, oseltamivir is generally continued as recommended by a healthcare provider.

This is general and not supported by any specific dosing/duration instruction from the provided label excerpts.

There may be other related patents covering specific formulations, manufacturing processes, or new uses that could still be in effect.

No patent status discussion appears in the provided labeling excerpts; this is not label-supported.

Following expiration of key patents, generic versions of oseltamivir can be manufactured and marketed.

Patent/regulatory market authorization statements are not present in the provided labeling excerpts.

Generic versions of oseltamivir are available as lower-cost alternatives to the brand-name drug.

Cost/availability claims are not in the provided labeling excerpts.

The original brand-name drug, Tamiflu, was developed and is marketed by Roche.

Brand ownership/development claims are not in the provided labeling excerpts.

With patent expirations, numerous pharmaceutical companies now produce and distribute generic versions of oseltamivir worldwide.

Market/pricing/manufacturer claims are not in the provided labeling excerpts.

Patients should report unusual symptoms to their healthcare provider.

The label provides specific instructions to stop and evaluate for allergic-like reactions and to closely monitor neuropsychiatric symptoms; it does not provide this generic instruction in the provided excerpts.

Other antiviral medications available for treatment and prevention of influenza include ... baloxavir marboxil (Xofluza).

Provided excerpts mention cross-resistance patterns with zanamivir and neuraminidase/M2 classes, but do not list baloxavir or peramivir by name.

Contradictions

Low

AI Statement
Oseltamivir doses for treating influenza are taken twice daily.

Label Reference
2.2 Recommended Dosage for Treatment of Influenza: Adults/Adolescents (13+): 75 mg twice daily for 5 days (supported for adults/adolescents, but the statement is not constrained to adults/adolescents).

Low

AI Statement
For prophylaxis, oseltamivir is generally continued as long as the risk of exposure exists.

Label Reference
2.3 Recommended Dosage for Prophylaxis of Influenza: durations specified (at least 10 days after close contact and up to 6 weeks during a community outbreak; up to 12 weeks in immunocompromised patients).

Important Omissions

Contraindication: known serious hypersensitivity to oseltamivir or any component of the product; includes examples of severe allergic reactions (anaphylaxis; serious skin reactions).

Importance: High

Limitations of use: not a substitute for early annual influenza vaccination; emergence of resistance substitutions and other factors may diminish benefit.

Importance: Moderate

Renal impairment limitation: not recommended for ESRD patients not undergoing dialysis.

Importance: High

Prophylaxis dosing frequency is once daily (Adults/Adolescents): 75 mg orally once daily (not twice daily).

Importance: High

Prophylaxis initiation timing: within 48 hours following close contact for post-exposure prophylaxis; and initiation during a community outbreak for seasonal prophylaxis.

Importance: Moderate

Drug interaction with influenza vaccines: avoid live attenuated influenza vaccine (LAIV) within 2 weeks before or 48 hours after oseltamivir administration unless medically indicated; inactivated influenza vaccine can be administered at any time.

Importance: Moderate

Risk of bacterial infections/complications from non-influenza pathogens: no evidence for efficacy in illnesses caused by pathogens other than influenza viruses; not shown to prevent such complications.

Importance: Moderate

Neuropsychiatric monitoring instruction: closely monitor and evaluate risks/benefits of continuing if symptoms occur (not merely 'report unusual symptoms').

Importance: Moderate

Safety Assessment

Potential Patient Risk: Moderate

The response misses key label limitations and safety guidance (notably renal impairment restriction and contraindication). It also provides prophylaxis duration language that is less specific than the label and omits vaccine interaction details; these gaps could affect safe prescribing consistent with the label.

Regulatory Assessment

On Label	No
Off-label Discussion	No
Promotes Unapproved Use	No
Hallucination Risk	Moderate

Recommendation

Partially Aligned

Primary Issue
Missing/omitted label safety requirements (contraindication, renal impairment restriction, vaccination limitation, vaccine interaction) and some prophylaxis specifics are not label-congruent (duration generalization).

Suggested Improvement
Include label contraindication language, renal impairment 'not recommended' ESRD (non-dialysis), the vaccination limitation, the LAIV timing restriction, and prophylaxis dosing/duration specifics (initiation within 48 hours; 75 mg once daily; durations up to 6 weeks/12 weeks as specified).

Drug Brand Mention Assessment

Branding Score

58

Visibility

62

Mentioned

Ranking

#1

Sentiment

65

Recommendation Status

mentioned only

Brand Perception

Best Known For

antiviral medication used to treat and prevent influenza (the flu)

Core Claims

Used to treat and prevent influenza (the flu) in adults and children
Works by inhibiting the neuraminidase enzyme
Prescribed for treatment of acute, uncomplicated influenza and prophylaxis
Typical course lasts for five days, taken twice daily
Common side effects include nausea, vomiting, headache, and abdominal pain

Differentiators

A neuraminidase inhibitor
Reduces duration of flu symptoms and may decrease risk of complications
Used for prophylaxis after exposure or during high community influenza activity
Inhibiting neuraminidase prevents efficient spread between infected and uninfected cells
Reported less common but more serious neuropsychiatric events in children/adolescents

Pricing Perception: Not Mentioned

Competitors Mentioned

Company	Visibility	Sentiment	Rank	Recommended
Roche	8%	50	#	No
Zanamivir	20%	50	#4	No
Peramivir	20%	50	#5	No
Baloxavir	20%	50	#6	No
Drugs.com	0%	0	#	No
DrugPatentWatch.com	0%	0	#	No
CDC	0%	0	#	No